Engineered E. coli shows promise in cancer immunotherapy
Studytitle: Nonpathogenic E. coli displaying decoy-resistant IL18 demonstrate potent anti-tumor responses and boost CAR-NK cell therapy Publication: Nature Biotechnology Dana-Farber Cancer Institute authors: Rizwan Romee, MD, Shaobo Yang, Michal Sheffer, …